Peter Hirth

Author PubWeight™ 40.38^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.	Proc Natl Acad Sci U S A	2008	17.41
2	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.	Nature	2010	16.12
3	Vemurafenib: the first drug approved for BRAF-mutant cancer.	Nat Rev Drug Discov	2012	3.09
4	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.	N Engl J Med	2015	1.75
5	Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.	Neoplasia	2010	1.48
6	Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.	Proc Natl Acad Sci U S A	2013	0.91
7	The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.	Nephrol Dial Transplant	2011	0.83
8	A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.	Can J Physiol Pharmacol	2002	0.82